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Abstract:  Type-I interferons (IFN-I) are cytokines essential for vertebrate antiviral 
defense, including against herpesviruses. IFN-I have potent direct antiviral activities and 
also mediate a multiplicity of immunoregulatory functions, which can either promote or 
dampen antiviral adaptive immune responses. Plasmacytoid dendritic cells (pDCs) are the 
professional producers of IFN-I in response to many viruses, including all of the 
herpesviruses tested. There is strong evidence that pDCs could play a major role in the 
initial orchestration of both innate and adaptive antiviral immune responses. Depending on 
their activation pattern, pDC responses may be either protective or detrimental to the host. 
Here, we summarize and discuss current knowledge regarding pDC implication in the 
physiopathology of mouse and human herpesvirus infections, and we discuss how pDC 
functions could be manipulated in immunotherapeutic settings to promote health over 
disease. 
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1. Introduction 
Herpesviruses are enveloped viruses, with genomes consisting in double-stranded linear DNA. Nine 
herpesviruses have currently been associated with diseases in humans (Table 1). Three herpesviruses 
have been identified in mice. Herpesviruses establish life-long persistent infections in their natural 
hosts, with a very high seroprevalence ranging from 30% to 90% depending on the country and on the 
virus. The infection is usually asymptomatic in immunocompetent individuals. Upon resolution of the 
acute phase of the primary infection, herpesviruses establish latent infection in specific cell types. A 
variety of stress conditions, including immunosuppression or inflammation, promote herpesvirus 
reactivation which can eventually lead to severe pathology (for review see [1]). Indeed, herpesviruses 
are some of the most common opportunistic agents encountered in AIDS patients and in recipients of 
bone marrow or solid organ transplantation. Herpesviruses harbor a very selective tropism for their 
host species, attesting to a very long history of co-evolution spanning several millions of years. The 
mouse cytomegalovirus (MCMV) cannot infect rats or humans, and reciprocally for the human or rat 
CMVs. The genome of herpesviruses is of considerable size and complexity as compared to that of 
many other viruses. Herpesviruses harbor a high number of genes that are not essential for their 
replicative cycle but that appear to have been selected for escape from, or hijacking of, the host 
immune system. However, reciprocally, the immune systems of the hosts have evolved 
counterstrategies to control the viruses. One of the earliest and most potent responses of the hosts to 
infections with herpesviruses is the production of type-I interferons (IFN-I). 
IFN-I were the first cytokines discovered, a little over 50 years ago, based on their direct, potent and 
broad antiviral activity [14,15]. More generally, IFN-I are now known to play an essential role in the 
global orchestration of antiviral immunity, by linking innate and adaptive immunity through multiple 
immunoregulatory functions [16]. For instance, IFN-I do not only play a crucial role in the control of 
the replication of many viruses, but they can also promote NK cell or CD8 T cell antiviral cytotoxic 
activity, either directly  [17-20] or through the licensing of accessory cells such as conventional 
dendritic cells (cDCs) [13,21-24]. In mammals, there are one IFN-β and more than ten different IFN-α, 
the exact number of which varies across species. All of these IFN-I exert their activities by engaging 
an ubiquitous receptor (IFNAR) composed of two chains (IFNAR1 and IFNAR2) [25]. Although any 
cell type could theoretically produce IFN-I (at least IFN-β) when infected by a virus, one cell type 
specialized in the production of high levels of multiple species of IFN-I in response to herpesviruses 
and many other viruses has been identified and characterized in the last decade. It has been named 
IFN-I producing cells (IPCs) or plasmacytoid dendritic cells (pDCs). Viruses 2009, 1                              
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Table 1. Most common parameters measured to study the impact of herpesvirus 
stimulation on pDC biology. 
     Impact on pDC biology 
Herpesviruses  natural 
host
IFN-I 
production
Infection  Maturation
$ 
Herpes Simplex virus 1  HSV-1  human Yes* [2] ND ND
Herpes Simplex virus 2  HSV-2  human Yes*
± [3] No [4] ND
Varicella-zooster virus  VZV  human ND ND ND
Human cytomegalovirus  HCMV  human  Yes [5,6,7]  No (blood pDCs) [6] 
Yes (tonsil pDCs) [7] 
Partial [8] 
Human Herpesvirus 6  HHV-6  human ND Yes [9]  ND
Human Herpesvirus 7  HHV-7  human ND Yes [10]  ND
Epstein-Barr virus  EBV  human Yes [11] ND Yes [11]
Human Herpesvirus 8  HHV-8  human ND ND ND
Murine cytomegalovirus   MCMV  mouse Yes*
± [12] No
± [13]  Yes
± [13]
* pDCs have been described to be the main IFN-I source upon herpesvirus stimulation. 
± including in vivo in mice 
$ maturation of pDCs following stimulation with herpesviruses in terms of CD40, CD80, CD86 and MHCII 
up-regulation 
ND: not determined 
In humans, pDCs are characterized by selective high level expression of the C-type lectin CLEC4C 
(also referred to as BDCA2) and of the immunoglobulin superfamily member LILRA4 (also referred 
to as ILT7). In mice, there are no orthologs of CLEC4C or LILRA4. Instead, mouse pDCs selectively 
express high levels of the C-type lectin SIGLECH and of the bone marrow stromal cell antigen 2 
(BST2/CD317) membrane marker. SIGLECH is also found on a subset of marginal zone macrophages 
in the spleen. BST2 is induced at low to intermediate levels on a variety of immune cell types upon 
stimulation with IFN-I, including cDCs, and is also constitutively expressed on plasma cells. 
Therefore, mouse pDCs can be rigorously identified as CD11c
intBST2
high or as CD11b
-SIGLECH
+. 
Although it has been frequently used, it is important to be aware that the combined expression of B220 
and CD11c is not adequate to identify mouse pDCs, as B220
+CD11c
+ cells also encompass other 
leukocyte populations including a subset of NK cells [26-29] and a precursor of cDCs [30]. While 
mouse and human pDCs are identified by different markers, they share many functional 
characteristics  [31] and selective expression of over 200 genes as compared to other leukocyte 
subsets [28]. Thus, there clearly is a very strong homology between mouse and human pDCs, such that 
the investigation of the functions of pDCs in vivo in the mouse model should be largely relevant for 
understanding their biology in humans. The initial discovery and the functional study of pDCs have 
been closely linked to the study of innate immune recognition of herpesviruses. Indeed, together with 
the influenza virus  [32-34], herpes simplex viruses were the very first viruses used to identify 
human [2] or mouse [35] pDCs in vitro, based on the much older observation that a rare cell type had Viruses 2009, 1                              
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the unique ability to rapidly recognize herpesviruses for consecutive high level production of IFN-
I [36,37]. We reported the first evidence that pDCs actually constitute the major source of systemic 
IFN-I production during a viral infection in vivo using MCMV as a model [12,32]. To the best of our 
knowledge, pDCs have been shown able to recognize, and respond to, all of the herpesviruses tested 
(Table 1). These observations suggest that pDCs may be amongst the earliest sentinels for detection of, 
and defense against, herpesvirus infections. The present work aims at reviewing the current knowledge 
regarding the role of pDCs in the orchestration of the immune responses against herpesviruses, not 
only focusing on their beneficial role for the host but also raising the question of their possible 
implications in immunopathology under defined conditions, leading to the discussion of whether and 
how pDC responses to herpesviruses could be used in antiviral immunotherapy or vaccination. 
2. pDCs Contribute to IFN-I Production and Viral Control during Herpesvirus Infections 
2.1. pDCs produce high levels of all IFN-I in vitro in response to herpesviruses 
In humans, pDCs were demonstrated to be the major source of IFN-I production within total 
peripheral blood mononuclear cells (PBMCs) upon in vitro stimulation with HSV-1 [2]. Indeed, on a 
per cell basis, purified pDCs produced up to a thousand fold more IFN-I than cDCs or monocytes. 
Moreover, depletion of pDCs led to over a hundred fold decrease in PBMC production of IFN-I. 
Resting human pDCs do not contain mRNA for IFN-I. Upon HSV-1 activation, human pDCs rapidly 
express mRNA of all the IFN-I family members, whereas cDCs do not [38]. Under these conditions, 
IFN-I mRNA constitute up to 60% of the total pool of pDC neo-synthesized mRNA, attesting to the 
tremendous energy allocation that pDCs dedicate to the production of these antiviral cytokines upon 
proper stimulation. Human pDCs also produce high levels of IFN-I in vitro in response to other 
herpesviruses including HCMV [5-8] and EBV [11]. In mice, pDCs were likewise demonstrated to be 
the major source of IFN-I production within total splenic leukocytes upon in vitro stimulation with 
HSV-1 [35] or MCMV [39]. Among all the cells producing IFN-I in response to herpesviruses, pDCs 
are characterized by the fact that their IFN-I production does not require endogenous virus 
replication [2,40]. Moreover, pDCs are not productively infected by MCMV [13,41] or HCMV [6,7]. 
However, the resistance of pDCs to herpesvirus infection is not absolute. It depends both on the virus 
and on the source of pDCs. HHV-6 or HHV-7 productively infect blood pDCs [9,10]. Tonsil pDCs 
have been recently reported susceptible to HCMV infection in contrast to blood pDCs [7]. 
In summary, pDCs are the main IFN-I producers among total circulating leukocytes stimulated in 
vitro with herpesviruses. In most instances, pDC IFN-I production does not require endogenous viral 
replication. Indeed, human blood and mouse spleen pDCs appear resistant to productive viral infection 
by several herpesviruses. 
2.2. pDCs are the major producers of IFN-I in vivo in mice infected with MCMV or HSV-2 
Using MCMV as a model, we were the first to report that pDCs are the major producers of IFN-I in 
vivo during a viral infection [12,32]. pDCs isolated from the spleen of d1.5 MCMV-infected mice 
produced high levels of IFN-I ex vivo without any restimulation, while the cytokines could not be 
detected in the supernatant from cDCs isolated from the same animals [13]. A dramatic decrease in ex Viruses 2009, 1                              
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vivo IFN-I production was observed in splenocytes depleted of pDCs. Moreover, systemic IFN-I 
production was dramatically reduced in infected animals upon anti-GR1 [12,32] or anti-BST2 [39] 
antibody-mediated pDC depletion. These results thus demonstrated that pDCs are the major producers 
of systemic IFN-I in vivo during MCMV infection, even though CD11b
+ cDCs that are infected by 
MCMV in vitro at a high multiplicity of infection can also produce significant levels of IFN-I [42]. 
This conclusion was further confirmed by several other complementary approaches. First, pDCs 
isolated from the spleen of MCMV-infected mice expressed much higher amounts of the mRNA for all 
the different IFN-α and IFN-β subtypes tested as compared to other splenocytes  [43] (Figure 1). 
Second, the vast majority of IFN-I expressing cells in vivo in the spleen of infected mice were 
demonstrated to be pDCs, using intracellular staining with specific antibodies on cell suspensions or 
tissue sections at 30-36 hours post-infection [43] or YFP-IFNb reporter knockin mice at 12-24 hours 
post-infection [44]. We showed that splenic pDCs were the major producers of IFN-I in three mouse 
strains: 129S2, BALB/c and C57BL/6 mice. In all these instances, IFN-I production by splenic pDCs 
took place relatively rapidly and was very transient since it was easily detectable around 36 hours but 
not at 24 hours or 44 hours post-infection [43]. Third, a deficient IFN-I production upon MCMV 
infection was observed in a knockin mouse strain (Ik
L/L mice) which harbors a selective block in pDC 
differentiation at an immature stage in the bone marrow consecutive to a hypomorphic mutation of the 
IKAROS transcription factor [45]. 
The intravenous infection of mice with another herpesvirus, HSV-2, also leads to a systemic IFN-I 
production that is abrogated upon anti-BST2 antibody-mediated pDC depletion [3]. Thus, no doubt 
remains that splenic pDCs are the major source of IFN-I during systemic infections of mice with 
several herpesviruses in vivo. Interestingly, an intra-vaginal challenge with HSV-2 also leads to a 
pDC-dependent IFN-I production, but only locally as the cytokines can be detected in the vaginal wash 
but not in the blood, consistent with the lack of dissemination of the infection in immunocompetent 
animals [46].  
Taken together these data highlight the primordial role of pDCs as major IFN-I producers in 
response to systemic or local herpesvirus infections in vivo. However, this phenomenon cannot be 
generalized to all viruses as pDCs are not the major producers of IFN-I with certain viruses such as 
lymphocytic choriomeningitis virus (LCMV) [12] or upon local infections of the airways such as with 
intranasal Newcastle disease virus (NDV)  [47] or influenza  [48,49] challenges. During reovirus 
infections, cDCs contribute as well as pDCs to IFN-I production locally in the intestine [50]. It is 
noteworthy that we could not detect any IFN-I production by pDCs from the blood, lymph nodes, liver 
or lung of MCMV-infected mice, despite high levels of viral replication in some of these organs [43]. 
This is consistent with a similar observation reported by the group of Shizuo Akira in the intravenous 
NDV infection model [47]. This suggests that splenic pDCs are especially prone to high level IFN-I 
production upon systemic acute viral infections as opposed to pDCs located in some other organs such 
as the liver or the lung. The mechanisms for this differential responsiveness to viral stimuli of pDCs 
from distinct tissues are not clear, although a role of the local cytokine milieu has been proposed [51]. Viruses 2009, 1                              
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Figure 1. Cytokine and chemokine mRNA expression by pDCs and cDCs isolated from 
MCMV-infected animals at 36 hours post-challenge. pDCs (red circles), CD8α cDCs (blue 
diamonds) and CD11b cDCs (green triangles) were purified from C57BL/6 mice injected 
with vehicle (open symbols) or infected with MCMV for 36 h (closed symbols). 
Pangenomic microarray experiments were performed with the total mRNA isolated from 
these cell populations [43]. The expression of mRNA (Y-axis, in arbitrary units in log10 
scale) encoding various innate cytokines and chemokines (X-axis) in the three DC subsets 
studied is represented. Genes were classified in 5 groups accordingly to their pattern of 
expression across the 6 types of biological samples examined, using the GeneCluster 
software. Group 1 corresponds to the IFN-I genes which are undetectable or expressed 
only at very low level under steady state conditions, but which are induced to extremely 
high levels specifically in pDCs after infection. Group 2 corresponds to genes that are 
induced in all DC subsets but to a higher level in pDCs. Group 3 correspond to genes that 
are strongly induced to a comparable extent in all three DC subsets. Group 4 corresponds 
to genes induced to higher levels in cDCs as compared to pDCs. Group 5 corresponds to 
genes induced to higher levels specifically in CD8α cDCs. 
 
 
2.3. pDC-derived IFN-I contribute to the control of MCMV or HSV-2 replication in vivo, but this 
defense mechanism may be redundant in mouse strains with other efficient innate antiviral immune 
effectors 
A crucial function of IFN-I is their ability to inhibit viral replication and dissemination [16]. Indeed, 
pDC depletion leads to enhanced local HSV-2 replication in mice infected intra-vaginally [46] and in 
the spleen or liver in animals infected intravenously [3], correlating with the major role of pDCs for 
local versus systemic IFN-I production in these experimental settings. Thus, pDC-derived IFN-I 
directly contributes to the control of HSV-2 replication in vivo in mice upon systemic or local 
infections. However, the picture appears much more complex for MCMV infection. In 129Sv mice, 
pDC-derived IFN-I likely contribute to MCMV control as anti-GR1  [12] or anti-BST2 (data not 
shown) antibody-mediated pDC depletion leads to a higher splenic viral load. In C57BL/6 mice, 
different approaches used to selectively affect pDC functions have led to different results. In vivo anti-Viruses 2009, 1                              
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GR1  [12] or anti-BST2  [39] antibody-mediated pDC depletion has no significant impact on viral 
replication in the spleen. Because this treatment is less efficient than in 129 mice (data not shown), it is 
not possible to rule out that residual pDCs still contribute sufficient IFN-I production to allow maximal 
antiviral effects. This interpretation could be consistent with the observation that complete abrogation 
of pDC IFN-I production in C57BL/6 mice leads to a significant increase in MCMV replication or in 
viral-induced mortality, as reported in the Ik
L/L mice which lack mature pDCs [45] or in interferon-
regulatory factor 7 (IRF7)
-/- mice which have lost pDC ability to produce IFN-I  [52]. However, 
because pDCs are not the only cell type affected in these two mutant mouse models, the interpretation 
of their phenotype is difficult. An alternative explanation for the differential impact of pDC depletion 
on MCMV replication in 129Sv versus C57BL/6 mice could be the specific capacity of the latter to 
mount other innate immune responses redundant for this function. Indeed, contrary to 129Sv mice, 
C57BL/6 mice have efficient anti-MCMV natural killer (NK) cell responses which are able to 
recognize and kill infected cells in vivo very rapidly after infection at the same time as pDCs are 
activated for IFN-I production [53]. This antiviral function of NK cells depends on their activation by 
IFN-I [22]. Thus, in C57BL/6 mice but not in 129Sv animals, low levels of residual IFN-I may be 
sufficient to promote efficient viral control by NK cells, even in the absence of strong direct antiviral 
effects of IFN-I, and irrespective of the cellular source of these cytokines.  
In humans, several case reports have been published describing patients suffering from severe 
herpesvirus infections associated with decreased numbers of circulating pDCs as compared to healthy 
controls and with an impaired IFN-I production ability as assessed by in vitro restimulation of their 
PBMCs with the virus [54-56]. EBV infection of humanized NOD-SCID mice was reported to lead to 
a decrease in the numbers of circulating pDCs and in the ability of PBMCs to produce IFN-I upon in 
vitro restimulation [11]. This raises the question of whether the pDC deficiency reported in certain 
patients with severe herpesvirus infections could be a consequence rather than a cause of the disease. 
In any case, interestingly, reconstitution of NOD-SCID mice with pDC-enriched human PBMCs 
delayed their mortality upon consecutive infection with EBV [11]. It has been recently shown that 
chronic infection of mice with LCMV causes a long-lasting impairment of pDC ability to produce 
IFN-I upon activation with viral type stimuli and enhances sensitivity to a secondary unrelated 
infection with MCMV  [57]. Thus, it has been proposed that enhanced sensitivity to opportunistic 
viruses in patients with human immunodeficiency type 1 (HIV-1) infection could in part result from 
decreased pDC responsiveness [57,58]. A recent study indeed shows that while IFN-I can be detected 
in the spleens of patients with chronic HIV-1 infection, pDCs appear to make only a very low 
contribution to this function [59] In this regard, it is striking that herpesviruses are amongst the most 
common opportunistic agents causing life-threatening disease in HIV-1-infected infants [60]  or  in 
AIDS patients [61,62] who have a dramatic reduction in pDC numbers and an impairment of pDC 
functions [63] in addition to the deregulation of many other immune functions. Reactivation of latent 
infections with herpesviruses, in particular HCMV, is also a major cause of morbidity and mortality in 
bone marrow or solid organ transplantation recipients  [64], who undergo immunosuppressive 
treatments known to profoundly affect pDC numbers or functions [65-67]. 
In summary, manipulation of pDC numbers or functions in mice and epidemiological analyses in 
humans strongly suggest that high level production of IFN-I by pDCs contributes to the control of 
infections by herpesviruses. However, its importance could vary significantly between individuals Viruses 2009, 1                              
 
 
390
depending on their capacity to concomitantly mount other immune responses redundant for this 
function. There is currently no experimental system available to the scientific community that allows 
the disruption of pDC functions in vivo in an entirely specific and completely efficient way. The 
genetic engineering of mouse models designed to fill this need should be seen as a priority in this 
research field, because this will be the only rigorous way to evaluate the role of pDCs in vivo in the 
defense against herpesviruses and more generally in the orchestration of the immune responses to viral 
infections. The recent demonstration that the conditional knockout of the transcription factor TCF4 
(also referred to as E2-2) in adult mice leads to a complete and selective loss of pDCs constitutes a 
significant advance towards this goal [68]. 
3. pDC Innate Antiviral Functions Are Not Restricted to IFN-I Production but Globally 
Contribute to the Orchestration of Inflammation and to the Activation of Other Innate Cells 
3.1. pDCs produce multiple cytokines and chemokines in response to viruses 
Mouse splenic pDCs isolated around 1.5 days after MCMV infection of different mouse strains do 
not only secrete high levels of IFN-I but also produce significant amounts of IL-12p70, TNF-α, and 
CCL3, and induce mRNA expression for a number of other cytokines and chemokines including IL-
1β, IL-6 and LTα  [12,13,43] (Figure 1). Conversely, however, other cytokines that can be 
concomitantly detected in the spleens of infected animals seem to be mostly expressed in other specific 
innate immune cell types, for example IFN-γ in NK cells [13] or IL-15 in cDCs (Figure 1). Like their 
murine counterparts, human pDCs activated with HCMV or HSV-1 are also induced to produce and 
secrete many cytokines and chemokines including TNF-α, IL-6, CXCL10 and CCL3 [8,69]. However, 
unlike their murine counterparts, human pDCs do not express IL-12 or only at extremely low 
levels [31,38]. pDCs can also produce anti-inflammatory cytokines such as IL-10 in response to EBV 
stimulation [11].  
3.2. pDC-derived cytokines and chemokines contribute to the activation of other innate immune 
effectors 
The soluble factors produced by pDCs can act in a paracrine manner to recruit other cell types to the 
site of infection and induce them to produce a second wave of cytokines or chemokines. During 
MCMV infection, by producing IFN-I and CCL3, pDCs likely contribute to the induction of such a 
cytokine/chemokine cascade which has been demonstrated to be critical for NK cell recruitment to the 
sites of viral infection allowing the local delivery of their immunoregulatory and antiviral effector 
functions [70]. In addition, pDC-derived IL-12 directly induces IFN-γ production by NK cells [13,22] 
while pDC-derived IFN-I induces NK cells to proliferate  [22] and to acquire cytolytic granules 
containing perforin and granzyme B, at least in part indirectly by instructing other cell types, most 
likely cDCs, to produce IL-15 and transpresent it to NK cells in association with the IL-15Rα 
chain [21,22,71,72]. Upon stimulation with HSV-1, pDCs have been reported to produce IL-18 and 
thus to most efficiently contribute to induce NK cell IFN-γ production [73]. Human pDCs stimulated 
with HCMV induce NK cells migration and IFN-γ secretion, but not cytotoxicity [5] which could be 
consistent with the poor expression of IL-15 by pDCs (Figure 1). More generally, stimulation of pDCs Viruses 2009, 1                              
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with herpesviruses  [69] as well as with other types of viruses including hepatitis C virus  [74] or 
influenza virus [75] induces them to produce a variety of cytokines/chemokines which recruit and 
activate other innate immune cell types including cDCs, monocytes and NK cells. Finally, pDCs do 
not contribute to the activation of other innate immune effectors solely by the production of soluble 
factors but also through cell-cell contacts as illustrated by the demonstration that the ligand for the 
glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL) is preferentially expressed on 
human pDCs upon HSV-1 stimulation and is critical to promote NK cell IFN-γ production and 
cytotoxicity [76]. 
In summary, although pDCs were initially characterized as professional IFN-I-producing cells upon 
in vitro stimulation with viruses or during viral infections in vivo, they also bear a significant 
contribution to the production of many other soluble factors under the same experimental settings. 
Thus, beyond their direct contribution to antiviral innate activities through IFN-I production, pDCs are 
very likely to play a critical role in the initiation and global orchestration of the recruitment and 
activation of other innate immune cells (Scheme 1). 
Scheme 1. Modulation of innate and adaptive immune responses by herpesvirus-activated 
pDCs. pDCs are able to sense infection with herpesviruses through TLR9 and/or TLR7. 
The triggering of these receptors in specialized endosomes, where they are preassembled 
with the MyD88 adapter molecule and the IRF7 transcription factor in multimolecular 
complexes, leads to the phosphorylation of IRF7 and its translocation to the nucleus where 
it associates with other partners to constitute a transcription initiation complex (TIC) able 
to induce the expression of IFN-I and other target genes. Largely due to their production of 
innate cytokines or chemokines, pDCs can exert a variety of stimulatory or inhibitory 
functions on other innate or adaptive immune cell types. The global effect of pDC 
responses on the overall immune response and on the promotion of health versus disease 
depends on the combination and levels of the cytokines that they produce as discussed in 
Scheme 2. 
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4. pDCs Are Equipped with a Unique Molecular Machinery for Herpesvirus Recognition and 
Downstream High Level IFN-I Production 
4.1. pDC activation by herpesviruses primarily relies on TLR9 recognition of unmethylated viral 
genomic CpG DNA sequences but RNA sensing through TLR7 can also contribute 
Before pDCs were discovered, IFN-I production during viral infections was believed to mainly 
occur in infected cells through the activation of intra-cytoplasmic sensors for viral RNA or DNA 
molecules such as the RNA-dependent protein kinase (PKR) or the more recently discovered RNA 
helicases RIG-I and MDA-5 [77]. However, pDCs are now known to be the major producers of IFN-I 
upon stimulation with herpesviruses as well as some other types of viruses in vitro, and also during in 
vivo infections with these same viruses [3,12,43,46,78], while pDCs are most often not productively 
infected [4,6,13,41,79]. This apparent paradox was solved by the demonstration that pDCs express a 
unique set of endosomal receptors and associated signaling components allowing the detection of RNA 
or DNA sequences derived from engulfed viruses or infected cells. Indeed, pDCs express Toll-like 
receptors (TLR) 7 and 9 [80] which are localized in a specific endosomal compartment where they can 
respectively recognize single stranded RNA versus unmethylated CpG DNA sequences and 
consecutively initiate a signaling cascade ultimately resulting in high level IFN-I production. RNA or 
DNA molecules are not present in endosomes under steady state conditions in healthy individuals [81]. 
Thus, pDCs have the unique ability to detect viral infections without the requirement of endogenous 
viral replication, because they must be able to take up oligonucleotides from viruses or infected 
cells [82] into specialized endosomes for TLR7 or 9 triggering. The membrane receptors that must 
confer pDCs the ability to selectively recognize and engulf viral particles or apoptotic debris from 
infected cells remain to be identified. 
MyD88 is a signaling adapter molecule used by all TLRs except TLR3 as well as by the receptors 
for IL-1 and IL-18. The study of MyD88
-/- mice has allowed to demonstrate a crucial role of this 
molecule for pDC IFN-I production in response to in vitro stimulations by virus type stimuli as well as 
in vivo during viral infections [80]. TLR9 appears to be the only MyD88-associated receptor necessary 
for IFN-I production during HSV-2 infection [83], which is consistent with the known presence of 
unmethylated CpG DNA sequences in the genome of herpesviruses. In contrast, during HSV-1 or 
MCMV infections, IFN-I production shows only a partial dependence on TLR9 [39,40,84,85]. This 
could be in part explained by the fact that other cells than pDCs contribute to IFN-I production, in a 
manner that is independent of MyD88 [39,84,86] but which may rely on intracellular detection of viral 
replication by cytoplasmic sensors for viral DNA  [87] or RNA (as documented for EBV  [88]). 
However, we have also recently shown a partial redundancy between TLR9 and TLR7 in the MyD88-
dependent pDC activation for IFN-I production during MCMV infection in vivo  [89]. Indeed, in 
TLR9
-/- mice, TLR7 can promote sufficient residual pDC IFN-I production to allow a better control of 
viral infection and an enhanced resistance to viral-induced lethality as compared to MyD88
-/- or TLR7
-
/-TLR9
-/- animals. The ability of pDCs to respond to a DNA virus through TLR7 is a strong argument 
in favor of their ability to engulf apoptotic bodies from dying infected cells for delivery of viral or host 
mRNA to TLR7-containing endosomes. Of note, TLR7 has recently been reported to be responsible 
for the activation of IFN-I production by cDCs upon infections with phagosomal bacteria [90]. Thus, Viruses 2009, 1                              
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TLR7 functions are clearly not restricted to the recognition of, and responses to, RNA viruses, but also 
extend to defense against herpesviruses and phagosomal bacteria. Interestingly, a cross-regulation 
between TLR9 and TLR7 has recently been demonstrated in mouse cDCs, whereby TLR9 
outcompetes TLR7 for association with the scaffolding molecule UNC93B1 which is required for the 
trafficking of all endosomal TLRs from the endoplasmic reticulum to the endosomes. Thus, in wild-
type animals, TLR responses in cDCs are biased towards DNA- but against RNA-sensing [91]. It will 
be interesting to determine whether this mechanism is also at play in pDCs, which have a particularly 
strong expression of TLR7 and an exquisite sensitivity to its specific ligands. 
4.2. pDC unique ability to rapidly produce high level IFN-I results from constitutive expression of 
IRF7 together with TLR7/9 and MyD88 in endosomal multimolecular complexes 
The unique ability of pDCs to produce very high levels of all subtypes of IFN-I in response to 
herpesvirus infections cannot be solely explained by their expression of TLR9 and by their ability to 
engulf viral particles or infected cells. Indeed, these two properties are shared with cDCs, especially 
the CD8α subset in the mouse, which still does not produce significant levels of IFN-I under the same 
experimental conditions. Indeed, additional properties have been demonstrated to contribute to the 
exquisite ability of pDCs to produce high levels of IFN-I upon viral stimulations (Scheme 1). 
IRF7 is the master transcription factor controling IFN-I production in response to viral type stimuli, 
as IRF7
-/- mice show dramatic decreases in IFN-I production and enhanced mortality in response to 
challenges with different viruses, including MCMV [52] or HSV-1 [92]. Human and mouse pDCs 
constitutively express very high levels of IRF7 [80]. In contrast, in cDCs and other cell types, IRF7 
expression is induced only secondarily to a first, IRF3-dependent, wave of IFN-β/α4 production [93] 
but is critical to drive the consecutive production of the other IFN-α suptypes in a positive feedback 
loop. Loss of IRF7 expression abolishes pDC responses to MCMV [52], HSV-1 and all the other viral 
stimuli that have been tested [92]. Thus, high constitutive expression of IRF7 strongly contributes to 
the unique ability of pDCs to produce high level of all IFN-I subtypes very rapidly upon viral 
stimulation. In addition, as compared to cDCs, pDCs are characterized by a long retention time of CpG 
desoxyoligonucleotides in dedicated, transferrin receptor
+, endosomes where preformed 
multimolecular complexes exist which bridge together TLR7/9 and their downstream signaling 
machinery including MyD88 and IRF7 [94,95]. 
4.3. Autocrine IFN-I activity promotes high level production of these cytokines by pDCs and 
contributes to protect them from productive viral infection 
The lack or low level of replication of certain herpesviruses and other viruses in pDCs may seem 
surprising considering the ability of many of these viruses to productively infect cDCs. The 
mechanisms that protect pDCs from productive viral infection are not entirely understood. However, 
autocrine IFN-I responses certainly play an important role as we initially reported by showing over a 
ten-fold increased proportion of infected pDCs in IFNAR
-/- versus WT mice challenged with an EGFP-
expressing MCMV [13]. In these experimental settings, the ability to respond to IFN-I did not only 
protect pDCs from viral infection but also further enhanced their ability to produce IFN-I by about 
four-fold [12]. However, a significant production of IFN-I by pDCs still occurred in IFNAR
-/- animals. Viruses 2009, 1                              
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In mice infected with vesicular stomatitis virus (VSV), pDCs have been demonstrated to produce IFN-
I in a feedback loop independent manner [96]. The impact of pDC autocrine IFN-I responses has also 
been studied recently in the context of NDV infection. A crucial role of this positive feedback loop 
was shown both for sustained IFN-I production by pDCs and for protecting them from productive viral 
infection [97]. Indeed, in IFNAR
-/- pDCs, IFN-I production is poorly sustained and entirely depends on 
viral replication in the pDCs and the detection of cytoplasmic viral RNA through mitochondrial 
antiviral signaling protein (MAV)-dependent pathways. Autocrine IFN-I activity has also been shown 
to protect pDCs from infection by mouse hepatitis virus [79]. Human pDCs are protected from HCMV 
infection due both to autocrine IFN-I effects and to other yet unidentified mechanisms [6]. 
The selection during evolution of a cell type specialized for IFN-I production in response to viral 
infection may seem paradoxical with the fact that, when productively infected, any cell type is 
theoretically capable of producing high levels of these cytokines, including cDCs [98]. However, the 
major differences between pDCs and other cell types in the molecular mechanisms in place for the 
sensing of the viral infections and for the downstream induction of IFN-I production are revealing. 
Indeed, in most instances, pDC IFN-I production does not require endogenous viral replication in the 
cytoplasm but only detection in endosomes of engulfed oligonucleotides derived from other infected 
cells or viral particles. In fact, pDCs appear resistant to productive viral infection by several 
herpesviruses. In addition, IFN-I production by pDCs is not strongly dependent on a positive feedback 
loop, because pDCs constitutively express IRF7 at very high levels. In contrast, IFN-I production by 
most other cell types requires detection of viral RNA or DNA in the cytoplasm, and hence endogenous 
productive viral replication. Under these conditions, viruses have evolved a variety of strategies to 
inhibit both IFN-I production and IFN-I responses in infected cells very early on after initiation of their 
replication [87,99-101]. Therefore, in infected cells, viruses do not only interfere with the intensity of 
the first wave of IFN-β/α4 but also greatly compromise the amplification loop for secondary induction 
of the other subtypes of IFN-α. It should be noted that HCMV has recently been reported to suppress 
IFN-I secretion by pDCs through its interleukin 10 homolog [102]. Nevertheless, pDCs may have a 
non redundant role in the rapid systemic production of IFN-I and the consecutive induction of a global 
innate antiviral state in the host under defined conditions of infection with herpesviruses, due to their 
general ability to escape viral interference with these functions. 
5. Multiple Mechanisms Dampen pDC Responses to Viral Stimuli 
Systemic innate cytokine responses can play protective antiviral functions but can also lead to 
severe immunopathology when too high. Thus, the benefits of activation of pDC antiviral defenses 
must be balanced against the risks of immunopathology. In this respect, it is likely that mechanisms are 
in place to finely tune the activation of pDCs depending of the nature and intensity of the 
environmental threats that they can perceive. The existence of such mechanisms is supported by the 
observation that certain autoimmune diseases including systemic lupus erythematosus (SLE) or 
psoriasis have been found to be associated with unbridled IFN-I production by pDCs [103-105]. Viruses 2009, 1                              
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5.1. pDCs express several endocytic receptors which signal through a specific ITAM-dependent 
pathway and inhibit TLR-induced cytokine production 
Several studies have recently demonstrated the existence of an ITAM-dependent signaling pathway, 
similar to that downstream of the B cell receptor, which is triggered on human pDCs by engagement of 
FcεRIγ-associated membrane receptors of the C-type lectin (CLEC4C/BDCA2) or immunoglobulin 
(LILRA4/ILT7) super-families, and which dampens pDC cytokine responses to TLR or viral 
stimulations in vitro [106-108]. This regulatory pathway must be evolutionarily conserved, because 
some of its most specific components including BLNK and CARD11 are selectively expressed in 
mouse pDCs as well [28]. Indeed, the mouse SIGLECH C-type lectin receptor which associates with 
the ITAM-bearing adaptor DAP12 has also been shown to inhibit pDC cytokine responses to TLR 
stimulations [109,110]. DAP12 functions dampen pDC cytokine production [110], including in vivo in 
a cell autonomous way during CpG challenge or MCMV infection [111]. Thus, it is likely that the 
mouse SIGLECH receptor modulates pDC function through the triggering of the same B cell receptor-
like intracellular signaling pathway as the human CLEC4C receptor, although these receptors are not 
orthologous. The natural ligands of human CLEC4C and mouse SIGLECH still remain to be 
identified. However, BST2 has been very recently identified in humans as a ligand for LILRA4. BST2 
is a membrane molecule induced on many cell types by IFN-I [112]. Thus, human pDCs are uniquely 
equipped to sense the paracrine response to their production of IFN-I, allowing for a negative feedback 
loop to prevent excessive production of the cytokines that could cause deleterious effects to the host. 
Future studies will likely show that this is also the case in the mouse. 
5.2. Other intrinsic inhibitory mechanisms contribute to dampen pDC activation 
Another negative feedback effect of IFN-I has been described in pDCs that is shared with cDCs. It 
relies on the IFN-I-dependent induction on DCs of the TAM receptor tyrosine kinases Axl, Tyro3, or 
Mer. These molecules associate with the α-chain of the IFN-I receptor and activate the suppressors of 
cytokine signaling-1 (SOCS-1) and SOCS-3 upon engagement by their ligands Gas6 or ProS which 
can themselves be produced by DCs [113]. Other cell-intrinsic mechanisms exist that also contribute to 
dampen pDC responses to TLR triggering, such as the engagement of the immunoreceptor tyrosine-
based inhibition motif (ITIM)-bearing membrane receptor DCIR in human pDCs [114]. Interestingly, 
engagement of DCIR on pDCs increases their capacity to present antigen to T lymphocytes. Targeted 
delivery of vaccine antigens to mouse pDCs via coupling to an anti-SIGLECH antibody also promotes 
the induction of adaptive immune responses [115]. Thus, the mechanisms that terminate the production 
of innate cytokines by pDCs during responses to viral type stimuli may not only be in place to prevent 
the development of a cytokine shock but also to switch pDC functions towards direct activation of 
adaptive immunity once their initial role in the orchestration of innate immune defenses has been 
fulfilled. Viruses 2009, 1                              
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5.3. The control of viral replication by IFN-I and other innate immune mechanisms decreases TLR 
ligand availability and contributes to dampen pDC activation 
In vivo during MCMV infection, pDC activation for innate cytokine production increases with the 
doses of viral inoculum used for the infection of a given mouse strain [116]. pDC cytokine responses 
to MCMV infection also increase dramatically in mice unable of efficient innate control of viral 
replication early after challenge, as a consequence of a selective impairment in antiviral NK cell 
activity, due either to antibody-dependent depletion of these cells or to the absence of the gene 
encoding the NK cell activation receptor specific for infected cells [116]. Reciprocally, early treatment 
of infected mice with an antiviral drug leads to a dramatic decrease of pDC cytokine production. 
Therefore, although innate cytokine production during MCMV infection is independent of endogenous 
viral replication in pDCs, it is tuned accordingly to the global level of viral replication in the host. 
Thus, rather than being the primary mechanism of defense against viral infections, high systemic 
production of IFN-I and other innate cytokines by spleen pDCs may represent a fail-safe mechanism. It 
may be turned on to maximal levels, at the risk of immunopathology, only in the case of high systemic 
viral replication associated to high levels of circulating ligands for TLR7 or TLR9, when other innate 
immune mechanisms have failed to efficiently control the virus. This hypothesis is supported by 
studies of airway infections of mice with viruses that do not belong to herpesviridae. For example, 
intranasal challenge with NDV leads to pDC production of IFN-I (in the spleen, specifically) only 
when the first line of defense made by alveolar macrophages is experimentally disrupted and the 
infection has spread systemically [47]. 
In summary, pDCs are equipped with a unique set of sensors and associated signaling pathways to 
rapidly sense a variety of viruses, in particular herpesviruses, and to respond by high level production 
of IFN-I and other innate cytokines or chemokines, while protecting themselves from viral infection. 
In this respect, pDCs appear to play an important, non redundant role in vivo in innate immune defense 
against herpesviruses and other viruses such as mouse hepatitis virus [78]. However, pDC activation 
during viral infections appears to be tightly controlled in intensity, space, and time, by a variety of 
mechanisms, which may be in place to tune the risk of cytokine shock to the level of threat posed to a 
specific host by a given viral infection. 
6. pDCs Constitute a Link between Innate and Adaptive Immunity 
pDCs are not only professional producers of IFN-I and key players in innate immune defenses 
against viral infections. They have also demonstrated ability to contribute to the induction and 
regulation of adaptive immunity. Depending on the maturation signals they receive as well as on the 
nature and concentration of the antigen, pDCs can have contrasting effects on adaptive immunity 
(Scheme 1). They can promote anti-viral cellular adaptive immunity either directly through cross-
presentation of exogenous antigens to CD8 T cells or indirectly through the promotion of cDC 
maturation. On the contrary, under different conditions, they can induce immune tolerance. Viruses 2009, 1                              
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6.1. pDCs can contribute to the promotion of antiviral adaptive immunity 
cDCs have been long known to be specialized in antigen processing and presentation to naïve T 
cells leading to the induction of specific adaptive cellular immune responses. By contrast, until 
recently, pDCs had often been reported to be poor activators of naïve T cells, owing to their purported 
lower efficiency to take up, process and present exogenous antigens (reviewed in [117]). However, 
detailed and kinetic analyses of the expression of MHC class I and II in DC subsets upon activation 
have shown contrasting responses of pDCs as compared to cDCs, suggesting that these cell types 
function in a distinct and complementary fashion for the induction and maintenance of adaptive 
cellular immune responses. 
Rapidly after antigen capture and receipt of maturation signals, cDCs very transiently upregulate 
and then drastically downmodulate antigen up-take as well as MHC class II neosynthesis and 
ubiquitination. This allows efficient, selective, and long-term presentation of the antigens that cDCs 
have encountered at the same time of receipt of the maturation signals, while the sampling and 
processing of the antigens encountered after maturation is shut off. Conversely, pDCs maintain MHC 
class II synthesis and ubiquitination after antigen capture, allowing continous sampling of the antigenic 
environment for processing and presentation to CD4 T cells [118,119]. Under conditions of systemic 
immune activation as occurs during infections with blood-borne pathogens, this specialization may 
allow pDCs to present to CD4 T cells some microbial antigens synthesized late after the initial 
encounter with the infectious agent, much more efficiently than cDCs. In the case of herpesviruses 
which are opportunistic pathogens, one could expect that cDCs are already activated by the primary 
infectious agents and are then impaired in their ability to respond to the secondary infection by the 
herpesviruses, whereas pDCs may still be efficient. 
Recently, both mouse and human pDCs have been shown able to cross-present exogenous antigens 
to efficiently activate naïve or memory CD8 T cells ( [120,121] and reviewed in [117]). Moreover, 
human pDCs have been demonstrated to harbor a unique, specialized endocytic compartment 
containing premade stores of MHC class I which allow rapid processing of exogenous antigens for 
cross-presentation to CD8 T cells [122]. Thus, it is quite possible that pDCs play a major role in the 
direct induction and maintenance of antiviral CD8 T cell responses during viral infections. However, 
very few studies have directly addressed the role of pDCs for T cell activation during infections with 
herpesviruses. 
pDCs isolated from MCMV-infected animals up-regulate CD80, CD86, CD40 as well as MHC 
molecules and efficiently prime naive CD8 T cells in vitro for proliferation and IFN-γ production, 
when pulsed with exogenous antigens [13]. However, neither the ability of pDCs to naturally process 
and present MCMV antigens, nor the role of pDCs in the global shaping of antiviral CD8 T cells 
responses, have been addressed during the course of MCMV infection. During MCMV infection, pDC 
IFN-I production was required to promote cDC maturation and thus likely helped the induction of anti-
viral adaptive cellular immune response  [13]. pDCs exposed in vitro to HSV-2 induced T cell 
proliferation, more strongly for CD8 T lymphocytes [4]. pDCs isolated from the draining lymph nodes 
of HSV-1-infected mice had only a poor ability to induce IFN-γ production by HSV-specific CD4 and 
CD8 T cells as compared to cDCs  [123,124], suggesting that pDCs did not have a major role in the Viruses 2009, 1                              
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direct priming of T lymphocytes during HSV-1 infection. However, in these experimental settings, 
pDCs promoted optimal functions of cDCs via cell-to-cell contacts involving CD2 and CD40L, which 
contributed to enhance HSV-1-specific CD8 T cell responses [123]. Finally, in vitro stimulation of 
pDCs with HCMV or influenza promoted B cell activation and their differentiation into specific 
antibody-secreting plasma cells, through IFN-I- and IL-6-dependent effects [8,125]. 
In summary, in response to viral stimulations in vitro, or in vivo upon stimulation with synthetic 
TLR ligands and targeted delivery of antigens through antibody coupling, pDCs have been 
demonstrated to have a strong ability to cross-present exogenous antigens for the activation of naïve 
CD8 T cells. In addition, pDCs also play a key role in linking innate and adaptive immunity through 
their production of immunoregulatory cytokines or chemokines which can promote the recruitment and 
activation of cDCs and lymphocytes. However, the importance of these functions in vivo for the 
control of infections with herpesviruses still remains to be established. 
6.2. pDCs can contribute to the negative regulation of adaptive immunity 
To promote health over disease, antimicrobial immunity must be tightly regulated to allow the 
mounting of effector responses of sufficient strength and adequate quality for the control of the 
invading pathogen, but to prevent the development of immunopathology as could result from 
exacerbated inflammation. This delicate balance can be achieved in part through negative feedback 
regulatory loops acting at the level of innate immune responses as discussed earlier for pDC activation. 
Immunoregulatory mechanisms are also in place to finely tune adaptive immune responses, and pDCs 
have been demonstrated to be able to contribute to this function. In response to EBV stimulation, pDCs 
can produce anti-inflammatory cytokines such as IL-10  [11]. HSV-1-stimulated pDCs can 
downmodulate CD4 T cell activation directly through the production of IFN-I and IL-10, and 
indirectly through the induction of regulatory CD4 T cells, suggesting that pDCs may contribute to 
prevent excessive, detrimental, adaptive immune responses during viral infections  [126]. The co-
culture of pDCs, but not cDCs, and CD4 T cells in the presence of HCMV leads to the induction of IL-
10 producing T cells [127]. pDCs have also been shown able to express the enzyme indoleamine 2,3-
dioxygenase 1 (IDO), which can induce T cell tolerance through tryptophan catabolism and 
downstream production of pro-apoptotic metabolites [128,129]. A role for pDC expression of IDO has 
been demonstrated in vivo in mice for the generation of an immunosuppressive environment in 
tumors [130]. In humans, the expression of IDO by pDCs has been proposed to contribute the immune 
deregulation during HIV-1 infection  [131,132]. However, to the best of our knowledge, there is 
currently no evidence that IDO can be expressed by pDCs in the course of infections by herpesviruses 
and that it can play a role in setting the balance between antiviral defense and immunopathology. The 
addition of an IDO inhibitor in cocultures of HSV-1-stimulated pDCs and CD4 T cells did not prevent 
the induction of regulatory T cells [126].  
To conclude, these data showed that, in response to certain herpesviruses, pDCs can secrete anti-
inflammatory cytokines and induce or activate regulatory T cells. However, these pDC functions have 
not yet been examined in vivo during herpesvirus infections. Regulatory T cells induced by pDCs 
could favor the development of highly specific adaptive immune responses targeted to the invading 
virus, by preventing bystander activation of T cells directed against other antigens, thereby Viruses 2009, 1                              
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contributing to promote antiviral defenses and to prevent immunopathology [133].  Interestingly, 
during intra-vaginal infections of mice with HSV-2, by controlling chemokine/cytokine production and 
overall immune activation in secondary lymphoid organs, regulatory T cells promote the trafficking of 
innate and adaptive antiviral effectors out of the lymph nodes to the site of infection for local control 
of viral replication [134]. Thus, taken together, these data suggest that the induction of regulatory T 
cells by pDCs may contribute to focus innate and adaptive antiviral immune responses to the 
appropriate antigens and anatomical sites to promote health over disease. 
7. pDC response to Herpesvirus Infections Is a Double-Edged Sword: It Contributes to the 
Control of Viral Replication but Can also Take Part in the Induction of Immunosuppression or 
Immunopathology 
As discussed above, pDCs are potent antiviral cells which can produce high levels of a number of 
cytokines or chemokines and strongly stimulate both the innate and adaptive immune systems. 
Although pDC functions are regulated by a number of activating or inhibitory mechanisms, situations 
have been described where pDC responses are deleterious for the host. The role of pDCs in the 
development of autoimmune diseases, including SLE or psoriasis, have been discussed in detail 
elsewhere [135]. Recent data have also suggested a possible deleterious role of pDCs in the context of 
certain viral infections. This should not be a surprise considering that IFN-I have long been known to 
be a double-edged sword able to promote either health or disease depending on the physiopathological 
context (Table 2).  
For the infections with HIV-1 or simian immunodeficiency virus (SIV), there has recently been a 
striking paradigm shift regarding the role of pDCs in the natural history of the disease. HIV-infected 
individuals show decreased number of pDCs and their PBMCs are impaired for IFN-I production upon 
in vitro restimulation. Therefore, it was first hypothesized that a lack of pDC responses contributed to 
the failure to control viral replication early on after primary infection  [63]. However, recently, 
evidences have been obtained of a massive IFN-I response during HIV-1 infection, starting early on 
during acute infection [136] and sustained thereafter [137,138]. This chronic production of IFN-I has 
been proposed to contribute to CD8 T cell disarming and uninfected CD4 T cell killing [139]. The 
cellular source of the IFN-I produced during chronic infection is debated  [59], but pDCs could 
contribute  [140,141]. More generally, pDCs have been reported to be hyperactivated during HIV 
infection and to likely contribute to immune deregulation and disease by a number of 
mechanisms [139,141]. Strikingly, comparisons between pDC responses of non human primate models 
with contrasting susceptibilities to SIV-induced disease have demonstrated much higher pDC 
activation in the susceptible rhesus macaques as compared to the resistant African green 
monkeys [142] or sooty mangabeys [138], associated with a polymorphism in the Irf7 gene between 
rhesus macaques and sooty mangabeys [138]. In summary, recent investigations strongly suggest that 
pDCs play a deleterious role for the host during infections with HIV-1 or SIV. This possibility has not 
yet been extensively examined during herpesvirus infections, but will be worth considering under 
specific conditions based on the data discussed below. Viruses 2009, 1                              
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Table 2. IFN-I responses to viral infections are a double edged sword.  
The goods of IFN-I responses   Ref.  The bads of IFN-I responses   Ref. 
Direct antiviral effects   [15]  Development of autoimmunity or 
immunopathology 
 [15,143] 
Promotion of cDC maturation   [13,23]  Induction of DC apoptosis   [144] 
promotion of cDC cross-presentation   [24]  Prevention of DC renewal   [145] 
promotion of NK cell activation   [19,22]  General inhibition of hematopoiesis   [146,147] 
Help to CD8 T lymphocytes   [17,18,20]  Anti-proliferative or pro-apoptotic effects 
on CD8 T cells 
 [15,148,149] 
Help to B lymphocytes   [150,151]  Susceptibility to bacterial surinfections   [152,153] 
 
7.1. Herpesviruses can exploit pDC functions to promote their replication 
Recently, the induction of IFN-β by TLR9 triggering on HCMV-infected fibroblasts has been 
reported to promote their survival and to increase their production of viral particles [154]. However, 
this proviral effect occurred only when fibroblasts were simulated with CpG shortly after infection. In 
contrast, a treatment concomitant to viral challenge almost completely abrogated fibroblast infection 
and virus production. Thus, it is unlikely that this mechanism plays a significant proviral role to the 
disadvantage of the host during infections with most herpesviruses in vivo, as systemic production of 
IFN-I by pDCs should lead to the induction of antiviral defenses in most cells before they encounter 
the virus. However, the possibility remains that this mechanism could have been exploited by 
herpesviruses which can productively infect pDCs such as HHV-6 and HHV-7  [9,10]. Some data 
suggest that pDCs could participate to the local replication and to the dissemination of HHV-6 and 
HHV-7, as skin lesions induced by the infections with these viruses have been reported to be infiltrated 
by infected pDCs [10], and infected pDCs can transmit the virus to stimulated T cells [9]. 
7.2. Excessive pDC activation during viral infections can contribute to immunosuppression or lead to 
immunopathology 
As mentioned earlier, IFN-I can promote either health or disease depending on the 
physiopathological context (Table 2). Therefore, high level production of IFN-I by pDCs such as 
occurs during certain herpesvirus infections could contribute to immunosuppression or even lead to 
immunopathology. Indeed, we have shown that high levels of pDC innate cytokine production during 
MCMV infection are associated with an ablation of cDCs and a significant delay in the induction of 
antiviral CD8 T cell responses for up to 48 hours [116]. This transient immunosuppression can be 
recapitulated by exogenous administration of IFN-I in mouse strains that mount low pDC responses to 
MCMV infection, pointing to a crucial role of pDC-derived IFN-I in this phenomenon [116]. This 
impact of pDC functions on the kinetics of induction of antiviral adaptive immunity is striking given 
the recent observation that better outcomes of early primary viral infection with LCMV in mice or SIV 
in macaques correlate with increased ratio between antigen-specific CD8 T cells and infected cells in Viruses 2009, 1                              
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situ very early after challenge [155]. TNF-α has been shown to contribute to the disease induced by 
MCMV infection, as it contributes to liver pathology independently of NK and T cell responses [156]. 
pDCs could also contribute to these effects since they are the major source of TNF-α early after 
infection in different mouse strains [43].  
7.3. Is-there a role for herpesvirus-dependent pDC activation in the triggering of certain autoimmune 
diseases? 
Because chronic IFN-I or TNF-α responses often occur in a variety of autoimmune diseases [157], it 
will be worth examining whether pDC activation by herpesvirus infections may contribute to the 
development of autoimmunity. As mentioned earlier, a deleterious role of pDCs has been proposed for 
SLE or psoriasis [103,104]. Although the etiology of these diseases is not entirely understood, it is 
possible that infections with certain herpesviruses could initiate the pathology in some patients. The 
possible implication of EBV infection in several autoimmune diseases including SLE is indeed 
debated [158,159].  
8. From the Bench to the Bedside: Exploiting pDC Responses to Herpesvirus Infections for 
Therapeutic Purposes 
8.1. Boosting pDC antiviral responses 
Studies in mice have demonstrated a TLR9- and MyD88-dependent protective role of local CpG 
administration following intravaginal infection with HSV-2 [160]. pDCs were recruited in the vaginal 
mucosa 24 hours after CpG treatment. Anti-BST2 antibody-mediated pDC depletion in vivo abrogated 
the protection. In humans with genital infection by HSV, topical application on the affected regions of 
a cream formulation of a TLR7 agonist, imiquimod, allows remission of the lesions  [161], likely 
through the local recruitment and activation of pDCs for IFN-I production. Importantly, this treatment 
has proven efficient even in the case of recurrent lesions caused by viruses resistant to the classical 
antiviral drug acyclovir [161]. This was the case for an AIDS-patient whose pDCs were unable to 
respond to HSV-1 upon in vitro restimulation but produced high levels of IFN-I upon exposure to 
imiquimod [54]. Thus, boosting pDC responses on genital lesions caused by herpesviruses, through the 
local administration of TLR7 or 9 agonists, can lead to efficient control of the virus and cure of the 
disease through activation of antiviral innate immunity, in complement or alternatively to the use of 
classical antiviral drugs directly inhibiting the viral DNA polymerase (Scheme 2). 
In mice, boosting pDC responses has also been shown to enhance resistance to systemic infection 
with MCMV or HSV-1. This has been achieved either through the systemic administration of the 
Thymosin-α1 peptide [41] or of FLT3L [162]. In both cases, enhanced protection against the viral 
infection resulted from increased IFN-I or IL-12 production. For the MCMV infection, this was shown 
to depend on the activation of the TLR9/MyD88/IRF7 pathway in pDCs and to lead to a higher NK 
cell activation. Since a deficiency in pDC responses has been proposed to be implicated in the 
susceptibility of bone marrow or solid organ transplant recipients to HCMV reactivation or primary 
infection  [65,67], therapeutic strategies aimed at restoring normal pDC functions in this 
physiopathological context may bring clinical benefits (Scheme 2). However, as compared to the local Viruses 2009, 1                              
 
 
402
activation of pDCs in skin or mucosa by topical application of TLR agonists, systemic activation of 
pDCs may bear increased risks of detrimental side effects. Thus, further studies will be required to 
determine the best strategy to harness pDCs for the promotion of efficient systemic innate antiviral 
defenses without triggering excessive inflammation and consecutive immunopathology. 
Scheme 2. Impact of the fine tuning of pDC activation on the promotion of health versus 
disease. During herpesvirus infections, disease can result either from immune failure to 
control viral replication early or from the development of immunopathology. Weak pDC 
activation could contribute to disease in the former case, and excessive pDC activation in 
the latter case. Immunopathology can cause immune-mediated damage to vital organs 
and/or compromise the ability of adaptive immunity to control viral replication later. Thus, 
a significant but controlled pDC activation is required to promote health over disease, by 
allowing early control of viral replication while not causing significant immunopathology. 
Therapeutic protocols aimed at boosting or dampening pDC responses could thus help to 
reach this balance and to fight disease under defined clinical conditions, as discussed in the 
body of this review. 
 
 
8.2. Dampening pDC activation 
As mentioned above, excessive pDC activation during infections with HIV-1/SIV or with MCMV 
can lead to an overwhelming production of IFN-I and other innate cytokines. This in turn can lead to 
immune deregulation, including delaying or disarming of adaptive immunity, or to the generation of a 
local inflammation which contributes to support viral replication and dissemination [163]. In addition, 
pDCs have been involved in autoimmune diseases for which certain herpesvirus infections have been 
suggested to be potential triggers  [158,159]. Thus, the dampening of pDC responses could be a 
reasonable component of immunotherapeutic strategies aimed at decreasing the immunopathology in Viruses 2009, 1                              
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these different conditions (Scheme 2). Interestingly, in a model of genital infection of macaques with 
SIV, the dampening of the pDC response locally in the vagina resulted in reduced local inflammation, 
including a decreased CD4 T cell infiltration, and led to a significant protection of the animals against 
repeated high dose challenge with SIV [163]. These effects were achieved by local application of 
glycerol monolaurate which dampened the activation of endocervical epithelial cells for CCL20 
production and therefore prevented the downstream CCR6–dependent recruitment of pDCs in the 
vagina. Dampening systemic pDC responses in vivo could theoretically be achieved by a number of 
ways, including treatments with antagonist ligands of the TLR receptors [164], or the administration of 
agonistic antibodies to the LILRA4 or CLEC4C receptors which are selectively expressed in pDCs and 
downmodulate their production of innate cytokines in response to TLR triggering [106-108]. However, 
it must be stressed that pDC responses should not be completely switched off, because this may lead to 
heightened viral replication, as recently demonstrated for inflammatory DCs in the case of a mouse 
model of intranasal influenza infection. Indeed, in this model, either excessive or absent inflammatory 
DC responses turned out to be deleterious for the host, due respectively to immunopathology versus 
loss of control over viral replication. In contrast, dampening of inflammatory DC responses through 
drug treatment allowed enhanced resistance to disease [165]. Thus, therapies aimed at dampening pDC 
responses to limit immunopathology in the course of viral infections should be combined with other 
treatments aimed at controling viral replication, such as antiviral drugs or immunotherapeutic 
restoration of the cytotoxic antiviral activity of NK cells or CD8 T lymphocytes. 
8.3. Exploiting herpesviruses as potent vectors for vaccination against other intracellular pathogens 
Herpesviruses are well controlled by immunocompetent hosts, since most humans are infected by 
HCMV, EBV, or HSV, and yet do not develop any clinical symptoms. All three of these viruses appear 
particularly efficient at activating pDCs. Therefore, it seems reasonable to consider that pDCs may 
contribute to the induction of the strong, protective, adaptive immune responses observed to occur 
naturally in most infected individuals. Interestingly, the ability to trigger a variety of TLRs and to 
activate multiple DC subsets, including pDCs, is part of the explanation that has been proposed for the 
high efficacy of the attenuated yellow fever virus vaccine [166]. In the case of herpesviruses, other 
factors are also likely to contribute to the induction of long-lasting protective adaptive immunity. In 
particular, this is the case of the inflation over time of the memory CD8 T cells directed against the 
products of immediate early genes [167]. This inflation occurs due to the natural boosts provided by 
expression of these antigens during partial reactivation of virus from latently infected cells over the 
lifetime of the infected individuals [168]. Therefore, it would be worth considering the exploitation of 
herpesviruses as potent vectors for vaccination against other intracellular pathogens or tumors. Indeed, 
this has been already done rather successfully in mouse models of vaccination against influenza or 
LCMV, where the target antigens had been introduced under the control of the promoter of the gene 
encoding the immediate early antigen-2  [169] as well as very recently in rhesus macaques for 
vaccination against SIV although expression of the vaccine antigens had been driven by the promoter 
of a structural gene which should not induce CD8 T cell memory inflation [170]. The role of pDCs in 
the success of these vaccination protocols would be interesting to evaluate. Viruses 2009, 1                              
 
 
404
9. Conclusion 
The various studies on pDCs in the context of infections by herpesviruses show a strong 
involvement of these cells in the antiviral immune response. Corresponding key issues are summarized 
in Table 3. Both in vitro and in vivo, pDCs are the major source of IFN-I during stimulations or 
infections by herpesviruses. IFN-I responses have been shown to play a critical role in the control of 
these viral infections, in particular in the case of MCMV or HSV2. pDCs have a unique ability to 
rapidly produce high and systemic levels of IFN-I, without the requirement for endogenous viral 
replication, upon engulfment of viral products. This can be explained by the constitutive expression in 
pDCs of a specific set of viral sensors, including TLR7 and TLR9, and of downstream signaling 
molecules including MyD88 and IRF7, arranged as preassembled multimolecular complexes in special 
endosomes. Although the expression of some of these molecules can be shared with other immune cell 
subsets, this is not the case of the whole set altogether as a preassembled endosomal multimolecular 
complex. In addition, pDCs are also able to produce multiple other cytokines or chemokines upon 
activation by herpesviruses. Thus, pDCs are likely to play a non redundant role in the induction and 
regulation of innate immune responses to herpesviruses. It should be noted that humans with genetic 
deficiencies in signaling components known to be critical for pDC IFN-I production in response to 
viral stimulation do not appear to suffer from life threatening viral infections, except for herpes 
simplex encephalitis [171,172]. This suggests that constitutive lack of pDC-derived IFN-I does not 
compromise the ultimate control of herpesvirus infections in humans in the absence of generalized 
immunodeficiency and in the context of the advanced health care system of developed countries. 
However, very recently, the sequencing and analysis of the ten human TLRs in over 150 individuals 
from various ethnicity demonstrated that the endosomal TLRs have evolved under strong purifying 
selection, including TLR7 and TLR9 which are selectively expressed to high levels in pDCs in 
humans. This suggests an essential non-redundant role of the endosomal TLRs in host survival “either 
via protective immunity against viral infections (present or past), or because of their additional 
involvement in other non immunity related processes of major biological relevance, or both” [173]. In 
any case, the possibility to harness pDC functions in the clinic to help treat infections with 
herpesviruses in immunocompromised individuals is promising. Topical treatments of genital lesions 
due to recurrent herpesvirus infections have indeed already given encouraging results. The role of 
pDCs in the regulation of adaptive immune responses to herpesvirus infections is less well understood. 
It is clear that pDCs can promote antiviral CD8 T cell responses through cDC instruction by soluble 
factors as well as cell-to-cell contacts. Whether pDCs bear a significant contribution to the direct 
priming of antiviral T lymphocytes in vivo during viral infections, as compared to cDCs, remains an 
open question on which future work will likely focus in the coming years. Moreover, pDCs are also 
able of inducing immunosuppression or tolerance under specific experimental conditions, which has 
not been yet studied in the context of infections with herpesviruses in vivo.  
While attention has been mainly drawn on the goods of pDC responses to herpesviruses, one should 
not ignore the possibility that pDCs may also contribute to disease for given herpesviruses in specific 
physiopathological contexts. From this point of view, it is revealing that for infections with HIV-1 or 
SIV, a paradigm shift recently occurred regarding the role of pDCs in the disease. In contrast to the 
initial hypothesis that pDC responses should be protective, the current idea is that pDCs play an Viruses 2009, 1                              
 
 
405
important deleterious role in the development of the disease. In the mouse model of MCMV infection, 
pDC hyperactivation can contribute to induce a transient suppression of antiviral adaptive immunity 
likely due in part to deleterious effects of high systemic levels of IFN-I on cDCs or CD8 T cells. pDCs 
have also been shown to be involved in a variety of autoimmune diseases for which infections with 
certain herpesviruses may constitute possible triggering agents. Under these physiopathological 
settings, therapeutic strategies aimed at dampening pDC activation may yield a clinical benefit. 
Significant progress has been made in the last couple of years on the deciphering of the innate 
functions of pDCs and their regulation during viral infections in vivo. However, further studies are 
required to improve our knowledge of the overall role of pDCs in the physiopathology of the infections 
with herpesviruses as well as other viruses, and to deepen our understanding of how the positive and 
negative mechanisms which regulate pDC functions integrate in time and space to promote health over 
disease. To this aim, the generation of novel mouse models specifically devoid of pDCs, or selectively 
affected in their functions, will be instrumental. In addition, the comparison of the outcome of 
herpesvirus infections and of the antiviral immune responses between non human primate models 
naturally differing in their pDC responses to TLR stimulations, such as macaques and sooty 
mangabeys [138], would be enlightening. 
Table 3. Key issues. 
Major concepts and outstanding questions regarding pDC responses to herpesviruses 
  IFN-I are innate cytokines endowed with potent direct and indirect antiviral activities. 
  The expression of the receptor for IFN-I is ubiquitous and allows widespread systemic effects of the 
cytokines. 
  IFN-I responses are complex and can induce protective antiviral responses or immunopathology depending 
on the timing, level and anatomical site of their production. 
  Herpesviruses can interfere with the induction of, or the responses to, IFN-I to escape immunity. 
  pDCs are the main IFN-I producers in response to many viruses including all the herpesviruses tested. 
  pDCs are able to sense herpesvirus infections through the TLR7/9 receptors in a MyD88 dependant manner. 
  pDCs produce a large panel of cytokines/chemokines and thus must play a major role in the orchestration of 
early inflammation and downstream activation of innate and adaptive immune effectors. 
  Mature pDCs can cross-present viral antigens for cognate CD8 T cell activation. 
  Excessive pDC activation during viral infections can contribute to immunopathology. 
  It is not known whether pDC responses to common herpesvirus infections could contribute to the 
development of certain autoimmune diseases in susceptible individuals. 
  It is not known whether, and how, pDCs are required for the induction and polarization of T cell responses 
during herpesvirus infections in vivo. 
  To rigorously evaluate the multiple roles of pDCs in vivo in the orchestration of antiviral immune responses, 
the genetic engineering of novel mouse models specifically devoid of pDCs or selectively affected in their 
functions will be crucial. 
  pDCs are interesting targets for the design of novel immunotherapeutic approaches against viral infections. 
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